Background. The TTC21B gene was initially described as causative of nephronophthisis (NPHP). Recently, the homozygous TTC21B p.P209L mutation has been identified in families with focal segmental glomerulosclerosis (FSGS) and tubulointerstitial lesions. Heterozygous TTC21B variants have been proposed as genetic modifiers in ciliopathies. We aimed to study the causative and modifying role of the TTC21B gene in glomerular and cystic kidney diseases. Methods. Mutation analysis of the TTC21B gene was performed by massive parallel sequencing. We studied the causative role of the TTC21B gene in 17 patients with primary diagnosis of FSGS or NPHP and its modifying role in 184 patients with inherited glomerular or cystic kidney diseases. Results. Disease-causing TTC21B mutations were identified in three families presenting nephrotic proteinuria with FSGS and tubulointerstitial lesions in which some family members presented hypertension and myopia. Two families carried the homozygous p.P209L and the third was compound heterozygous for the p.P209L and a novel p.H426D mutation. Rare heterozygous TTC21B variants predicted to be pathogenic were found in five patients. These TTC21B variants were significantly more frequent in renal patients compared with controls (P ¼ 0.0349). Two patients with a heterozygous deleterious TTC21B variant in addition to the disease-causing mutation presented a more severe phenotype than expected.
A B S T R A C T
Background. The TTC21B gene was initially described as causative of nephronophthisis (NPHP). Recently, the homozygous TTC21B p.P209L mutation has been identified in families with focal segmental glomerulosclerosis (FSGS) and tubulointerstitial lesions. Heterozygous TTC21B variants have been proposed as genetic modifiers in ciliopathies. We aimed to study the causative and modifying role of the TTC21B gene in glomerular and cystic kidney diseases. Methods. Mutation analysis of the TTC21B gene was performed by massive parallel sequencing. We studied the causative role of the TTC21B gene in 17 patients with primary diagnosis of FSGS or NPHP and its modifying role in 184 patients with inherited glomerular or cystic kidney diseases. Results. Disease-causing TTC21B mutations were identified in three families presenting nephrotic proteinuria with FSGS and tubulointerstitial lesions in which some family members presented hypertension and myopia. Two families carried the homozygous p.P209L and the third was compound heterozygous for the p.P209L and a novel p.H426D mutation. Rare heterozygous TTC21B variants predicted to be pathogenic were found in five patients. These TTC21B variants were significantly more frequent in renal patients compared with controls (P ¼ 0.0349). Two patients with a heterozygous deleterious TTC21B variant in addition to the disease-causing mutation presented a more severe phenotype than expected.
Conclusions.
Our results confirm the causal role of the homozygous p.P209L TTC21B mutation in two new families with FSGS and tubulointerstitial disease. We identified a novel TTC21B mutation demonstrating that p.P209L is not the unique causative mutation of this nephropathy. Thus, TTC21B mutation analysis should be considered for the genetic diagnosis of families with FSGS and tubulointerstitial lesions. Finally, we provide evidence that heterozygous deleterious TTC21B variants may act as genetic modifiers of the severity of glomerular and cystic kidney diseases.
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I N T R O D U C T I O N
Identification of the TTC21B gene as causative of focal segmental glomerulosclerosis (FSGS) has broadened the phenotypic variability associated with this gene, initially described as causative of nephronophthisis (NPHP) [1, 2] . The TTC21B gene encodes the ciliary protein IFT139, a component of the intraflagellar transport complex A required for retrograde intraflagellar transport in the cilium [3] .
Mutations in the TTC21B gene have been identified in nine ciliopathy patients: three with Jeune asphyxiating thoracic dystrophy (JATD), a chondrodysplasia that often leads to death in infancy [2, 4] ; three with NPHP and extrarenal manifestations [2, 5] and three with isolated NPHP, all of whom carried the 2] . The homozygous p.P209L mutation was identified in seven families with a primary diagnosis of FSGS [1] . Therefore, a total of 16 families with TTC21B mutations have been reported, 10 of which carried the homozygous p.P209L mutation. All of these 10 families were found to share the same haplotype, indicating a founder effect for this mutation in patients of Portuguese or North African origin. Reexamination of the renal biopsies of these patients revealed FSGS together with tubular lesions characteristic of NPHP disease. Their clinical features were late-onset proteinuria, high blood pressure and end-stage renal disease (ESRD) between 15 and 32 years. Functional studies on the effect of this mutation showed that it partially altered cilia structure, cell migration and cytoskeleton, suggesting a hypomorphic effect [1] .
The phenotypic variability observed in glomerular and cystic hereditary kidney diseases supports the hypothesis that mutations in multiple genes encoding proteins that converge in common pathomechanistic pathways may influence clinical presentation and outcome. Heterozygous TTC21B variants have been suggested to interact in trans with other disease-causing genes and contribute as putative second-site modifiers in patients with cystic disease. Therefore, the TTC21B gene has been proposed to have both a causative and a modifying role in these patients [2] . To date, the possible effect of heterozygous TTC21B variants in glomerular diseases has not been studied.
Here, we aimed to study the causative role of TTC21B gene mutations in our cohort of patients with a primary diagnosis of FSGS or NPHP and no previously identified mutations, as well as to assess the contribution of heterozygous TTC21B modifying alleles to glomerular and cystic kidney diseases.
M A T E R I A L S A N D M E T H O D S

Patients
A cohort of 187 patients with putative or molecularly confirmed inherited glomerular or cystic disease was analysed for TTC21B mutations. To study the causative role of the TTC21B gene, we considered 15 patients with steroidresistant nephrotic syndrome (SRNS)/FSGS with likely genetic aetiology, in whom no mutations had previously been identified in 26 glomerular disease genes [6] . We also included two patients with NPHP disease in whom the homozygous NPHP1 deletion had been ruled out. To study the putative modifying role of the TTC21B gene, we included the complete cohort, except for the three cases with TTC21B causative mutation. In most of these patients, a disease-causing mutation had been previously identified and the results have been partially published [6, 7] . These 184 patients had the following diagnosis: 48 autosomal dominant polycystic kidney disease (ADPKD), 24 autosomal recessive polycystic kidney disease, 6 HNF1B nephropathy, 6 tuberous sclerosis, 2 medullary cystic kidney disease, 1 NPHP, 47 Alport syndrome (AS) and 50 SRNS/FSGS. The study was approved by the Institutional Review Board and all participants gave their informed consent.
Sequencing and data analysis
All 29 TTC21B exons and intron boundaries (plus 100 bp at each end) were sequenced by targeted massive parallel sequencing. Libraries were prepared with the TruSeq DNA Sample Preparation Kit (Illumina, San Diego, CA, USA), according to the manufacturer's instructions. Enrichment was performed with the custom NimbleGen SeqCap EZ Choice Library (Roche Nimblegen, Madison, WI, USA). Our design included probes to target additional genes beyond the scope of this study. Sequences were run on a HiSeq2000 platform (Illumina). Data analysis was performed with an in-house developed pipeline [8] . Briefly, all variants were required on both sequenced DNA strands and to account for !20% of total reads in that site. Polymorphisms present in !5% in dbSNP 138, the 1000 Genomes Project and the Exome Variant Server were discarded. Common benign variants and recurrent artefact variant calls were filtered out using our in-house exome variant database. All candidate pathogenic variants in the TTC21B gene were validated by conventional polymerase chain reaction amplification and Sanger sequencing.
Evaluation of the pathogenicity of the variants
The pathogenicity of the missense variants was evaluated considering their conservation among orthologs, population data and three in silico predictors (SIFT, Polyphen and Mutation Taster). Segregation of these variants with the disease was assessed for all available family members. The missense variants conserved among orthologues, with a minor allele frequency <0.01, and predicted to be deleterious by all the in silico predictors used, were considered to be pathogenic. Truncating mutations were considered definitely pathogenic.
Evaluation of the putative modifying role of TTC21B deleterious variants
To study the putative contribution of TTC21B deleterious alleles to cystic and glomerular diseases, a case-control association study was performed. The allelic frequencies of TTC21B pathogenic variants in our cohort of 184 patients (368 alleles) and 2504 controls (5008 alleles) were compared by means of the two-tailed Fisher's exact test. A P-value <0.05 was considered statistically significant. Allelic frequencies of control individuals were obtained from 1000 Genomes data phase III [9] .
R E S U L T S TTC21B causative mutations
We identified disease-causing mutations in the TTC21B gene in 3 of the 17 FSGS/NPHP cases (Table 1) . Family 64 is a Spanish kindred with two siblings presenting with FSGS ( Figure 1 ). Patient 64-1 presented with nephrotic proteinuria at the age of 4 years, and myopia. She did not respond to corticosteroid and immunosuppressive therapy and reached ESRD at the age of 6 years. Her renal biopsy showed FSGS with diffuse interstitial inflammatory infiltrate. Her brother (64-2) was diagnosed at the age of 6 years, due to his sister's disease, and presented with nephrotic proteinuria, chronic kidney disease
(CKD) and high myopia. His biopsy findings showed FSGS with atrophic tubules and interstitial inflammatory infiltrate. He was not treated with corticosteroid or immunosuppressive therapy and he reached ESRD at the age of 8 years. Both siblings received a kidney transplant with no recurrence of the disease after 8 years of follow-up. They carried compound heterozygous TTC21B mutations: c.626C>T (p.P209L) and c.1276C>G (p.H426D) located in exons 6 and 11, respectively.
The p.P209L mutation has been reported to have a hypomorphic effect [1, 2] . The p.H426D variant has not been previously described in the literature. This variant is predicted to be pathogenic because it alters an amino acid conserved throughout evolution to Caenorhabditis elegans, and it is predicted to be deleterious to protein function by three publicly available programmes (SIFT, Polyphen and Mutation Taster). Population data show that this variant is absent in 280 control chromosomes and the 1000 Genomes database, whereas it has been reported once (1/119278) in the ExAC database ( Table 2) .
Family 22 is a Moroccan kindred with two affected siblings. The only available family member was a 12-year-old girl diagnosed with nephrotic proteinuria and CKD at 12 years of age. She came to our hospital at the age of 14 years due to a hypertensive crisis presenting with ESRD. Her renal biopsy showed only three glomeruli, all with global sclerosis, tubulointerstitial fibrosis and atrophic tubules. She received a kidney transplant, with no recurrence of the disease after 2 years. She carried the homozygous p.P209L mutation. The only information from her brother was that he reached ESRD at 23 years of age.
Family 374 is a Moroccan kindred with five children, two of them affected. Patient 374-1 was diagnosed due to a hypertensive crisis at 8 years old. He presented with nephrotic range proteinuria, CKD stage V and high myopia, and his renal biopsy showed FSGS with interstitial fibrosis and tubular atrophy. He was resistant to steroid and immunosuppressive therapy and reached ESRD 2 months after diagnosis. Patient 374-2 has recently been diagnosed at the age of 17 years with nephrotic
Contribution of TTC21B-modifying alleles to glomerular and cystic diseases
We identified rare heterozygous TTC21B variants predicted to be pathogenic (Table 2) in 5 of the 184 patients: 4 with glomerular disease and 1 with cystic disease (Table 3) 
Two of the five patients with a TTC21B variant, in addition to the disease-causing mutation, presented a more severe phenotype than expected. Patient 61 with ADPKD presented with enlarged polycystic kidneys, high blood pressure and CKD stage IV at the age of 36 years. He carried a de novo missense mutation in the PKD1 gene and additionally the p.L1002V TTC21B variant. He did not bear other candidate pathogenic variants in PKD1/PKD2/PKHD1/HNF1B genes [10] . Patient 82 presented with microhaematuria, full-blown nephrotic syndrome and high blood pressure at 28 years of age. Her renal biopsy showed FSGS with tubular atrophy and interstitial fibrosis and she reached ESRD at 32 years of age. She carried a COL4A3 missense mutation in the heterozygous state together with a frameshift mutation in TTC21B. She had no other candidate pathogenic variants in the 26 glomerular gene panel [6] .
The remaining three patients carrying an additional TTC21B variant had childhood-onset recessive diseases with short-term follow-up. Patient 186 was a 9-year-old girl with haematuria (onset at 11 months), non-nephrotic proteinuria (onset at 3 years), hearing loss (onset at 7 years) and hyperuricemia with normal renal function. Genetic diagnosis confirmed autosomal 
D I S C U S S I O N
In this study, we confirmed the causative role of TTC21B recessive mutations in patients with both FSGS and tubulointerstitial lesions and found that this phenotype is not caused by only homozygous p.P209L. Our findings support a putative modifying effect of rare TTC21B variants on glomerular and cystic disease severity based on the clinical manifestations of patients carrying heterozygous TTC21B variants in addition to the causative mutation. Genotype-phenotype correlations in patients carrying recessive TTC21B mutations have been established. Patients with at least one truncating or splice site mutation exhibit JATD or early onset NPHP with extrarenal involvement [2, 4] , whereas all patients carrying the homozygous p.P209L have isolated renal disease and display both FSGS and tubulointerstitial lesions on renal biopsy [1] (cf. families 22 and 374 described here). Moreover, our family 64 demonstrates that missense mutations different from the homozygous p.P209L can also cause this phenotype. A total of 23 patients with the FSGS and tubulointerstitial lesions due to homozygous or compound heterozygous missense mutations in the TTC21B gene have been described: 18 reported patients (10 families) [1] plus the 5 patients (3 families) of this study. Clinically, these patients presented with childhood or adult onset of proteinuria (in the nephrotic or non-nephrotic range) and a rapid progression to ESRD. Interestingly, the two affected siblings carrying the p.P209L and p.H426D mutation in the TTC21B gene had an younger age at onset of proteinuria (4 and 6 years) than the homozygous p.P209L patients (8-30 years, median 16 years). High blood pressure was present in 17 of the 23 cases (74%), indicating that it is a frequent clinical feature in patients with TTC21B mutations. Myopia was reported in 5 of 23 patients (22%). Given the rapid progression of the renal disease in these patients, it is difficult to determine whether the tubuloglomerular involvement is the primary lesion or the consequence of this rapid deterioration in renal function, but the focal and segmental aspect of the glomerular lesion and the interstitial infiltrate point to a specific pathologic setting for this disease.
Functional studies in zebrafish and mammalian cells have demonstrated that the p.P209L mutation is a hypomorphic allele because it allows partial function of the protein [2] . In human mature podocytes, the p.P209L mutation has been demonstrated to cause a partial alteration of the microtubule network that may affect cytoskeleton dynamics and destabilize podocyte architecture [1], thus supporting the hypothesis of its hypomorphic effect. To the best of our knowledge, the p.H426D mutation has not been previously reported in the literature, but its complete conservation throughout the evolution, the nonconservative nature of the substitution and the predicted deleterious effect by three different in silico tools strongly support its pathogenicity. Based on the earlier onset of proteinuria in the siblings carrying p.H426D, this variant might be more deleterious than the p.P209L mutation, although an effect of other modifying factors cannot be excluded.
TTC21B mutations were described to have a dual role, as causative of ciliopathies and second-site modifiers in patients with cystic diseases. This modifying role of heterozygous TTC21B variants was suggested by Davis et al. [2] based on their significant enrichment in ciliopathy patients. In our cohort, we did not find significant enrichment for the total set of rare TTC21B pathogenic variants. However, when considering the five variants identified in patients, a significant association of the TTC21B gene with glomerular and cystic kidney diseases was found. The fact that, in our case-control study, we did not observe significant enrichment for the total set of rare TTC21B pathogenic variants might be explained by several differences between the two studies: (i) Davis et al. studied NPHP-related ciliopathies, while our cohort included mostly polycystic kidney diseases (PKDs) and glomerular diseases; (ii) the smaller size of our case cohort and (iii) Davis et al. sequenced their control group, while we obtained control data from 1000 Genomes. Mutations in multiple renal disease genes may explain some of the phenotypic variability in glomerular and cystic hereditary kidney diseases. Bergmann et al. [10] described severely affected patients with PKD who carried, besides their familial mutation, additional alterations in PKD genes, which likely aggravate their phenotype. We recently described an increased disease severity in patients carrying mutations in an SRNS gene and also in the COL4A3 gene [6] . Here, we describe two patients with a TTC21B variant, in addition to a heterozygous disease-causing mutation, who presented a more severe phenotype than expected. Patient 61 with ADPKD, carrying a missense PKD1 mutation and a TTC21B heterozygous variant, presented with CKD stage IV at 36 years, whereas patients with PKD1 nontruncating mutations have a median age at ESRD of 68 years [11] . Patient 82 with autosomal dominant Alport syndrome (ADAS) reached ESRD at 32 years, while only $29% of ADAS patients progress to ESRD at a mean age of 56 years [12] . Additional studies are needed to confirm the contribution of deleterious TTC21B alleles to the severity of glomerular and cystic diseases.
In conclusion, TTC21B mutation analysis should be considered for the genetic diagnosis of patients with FSGS and tubulointerstitial lesions who may also have hypertension and myopia, especially in familial cases. Our results suggest that deleterious TTC21B alleles likely aggravate the phenotype of patients with glomerular and cystic inherited diseases, adding support to the proposed modifier role of TTC21B alleles.
